성장을 멈추지 마세요

체험은 만족하셨나요?

현재 45,775명이 마이메르시로 공부 중이에요

지식 자료를 소장하고 멋진 의료인으로 성장하세요

학습 자료 둘러보기 →
Phenylketonuria(PKU) | 마이메르시 MyMerci
제안하기

뭔가 하고 싶은 말이 있는거야?

0 / 2000
컨텐츠 수정하기

컨텐츠 내용을 수정할 수 있습니다

수정하기
닫기

Phenylketonuria(PKU)

NCLEX Review Guide: Phenylketonuria (PKU)

Pathophysiology & Etiology

Disease Process

  • Phenylketonuria (PKU) is an autosomal recessive inborn error of metabolism characterized by a deficiency in the enzyme phenylalanine hydroxylase, which normally converts phenylalanine to tyrosine. Without this enzyme, phenylalanine accumulates in the blood and tissues, causing neurological damage.
  • The incidence of PKU is approximately 1 in 10,000-15,000 births in the United States, with higher rates in some populations like those of Northern European descent.

Key Points

  • PKU is caused by a mutation in the gene that codes for phenylalanine hydroxylase (PAH) enzyme.
  • Without treatment, phenylalanine and its metabolites accumulate to toxic levels in the blood and tissues.

Clinical Manifestations

Signs and Symptoms

  • Untreated infants with PKU appear normal at birth but develop symptoms within a few months, including intellectual disability, seizures, behavioral problems, and motor deficits.
  • Physical characteristics may include fair skin, blue eyes, and eczema due to decreased melanin production (tyrosine is a precursor to melanin).
  • Children may develop a "musty" or "mousy" odor due to phenylacetic acid in urine and sweat.

Key Points

  • Early symptoms are often subtle but progressive neurological damage occurs if untreated.
  • The characteristic odor is described as "musty" or similar to "mouse urine."

Clinical Scenario

A 2-week-old newborn returns for follow-up after the pediatrician receives positive newborn screening results for PKU. The infant appears healthy with no symptoms, but the phenylalanine level is 16 mg/dL (normal: <2 mg/dL). The parents are confused because their baby "looks perfectly fine" and question the need for dietary restrictions.

Diagnosis & Assessment

Screening and Diagnostic Tests

  • Newborn screening is mandatory in all 50 states and typically performed 24-48 hours after birth using a heel stick blood sample collected on filter paper.
  • Positive screening results require confirmation with quantitative blood phenylalanine levels; levels exceeding 6 mg/dL with normal tyrosine levels confirm the diagnosis.
  • Genetic testing may be performed to identify specific mutations and for genetic counseling purposes.

Key Points

  • Newborn screening is crucial as symptoms are not present at birth but irreversible damage occurs without early treatment.
  • False negatives can occur if screening is performed before 24 hours of age or before adequate protein intake.

Treatment & Management

Dietary Management

  • The primary treatment is a phenylalanine-restricted diet that must be initiated before 3 weeks of age to prevent neurological damage.
  • The diet consists of measured amounts of phenylalanine from natural foods combined with a phenylalanine-free medical formula that provides protein, vitamins, and minerals.
  • Regular monitoring of blood phenylalanine levels guides dietary adjustments, with target levels typically between 2-6 mg/dL for children and 2-10 mg/dL for adults.

Key Points

  • Treatment must begin within the first few weeks of life to prevent irreversible neurological damage.
  • The diet must be maintained throughout life, including during adulthood.

Pharmacological Management

  • Sapropterin (Kuvan) is a synthetic form of tetrahydrobiopterin (BH4), a cofactor for phenylalanine hydroxylase that may enhance enzyme activity in patients with some residual enzyme function.
  • Approximately 20-50% of patients with PKU respond to sapropterin, allowing for increased dietary phenylalanine tolerance.

Key Points

  • Medication does not replace dietary management but may allow for less restriction in responsive patients.
  • Response to sapropterin is determined through a trial period with careful monitoring of phenylalanine levels.

Maternal PKU

  • Women with PKU who become pregnant require strict metabolic control before conception and throughout pregnancy to prevent maternal PKU syndrome in the fetus.
  • Elevated maternal phenylalanine levels cross the placenta and can cause microcephaly, intellectual disability, heart defects, and intrauterine growth restriction in the developing fetus, even if the fetus does not have PKU.

Key Points

  • Target phenylalanine levels should be 2-6 mg/dL before conception and throughout pregnancy.
  • Maternal PKU syndrome can affect any fetus (with or without PKU) if maternal levels are not controlled.

Nursing Care

Nursing Assessment

  1. Assess nutritional status, including growth parameters (height, weight, head circumference) at each visit.
  2. Monitor developmental milestones and perform age-appropriate developmental screening.
  3. Evaluate for signs of dietary non-adherence, including behavioral changes, concentration difficulties, or academic problems.
  4. Assess family coping and need for additional resources or support.

Key Points

  • Regular assessment of growth and development is essential to detect early signs of inadequate nutritional intake or poor metabolic control.
  • Assessment should include both physiological parameters and psychosocial adaptation to the chronic condition.

Nursing Interventions

  • Provide comprehensive education to parents about PKU, including the importance of diet adherence, food measurement, formula preparation, and blood level monitoring.
  • Teach parents to maintain detailed food records and calculate phenylalanine intake.
  • Support families through developmental transitions, especially when the child enters school, adolescence, and independent living.
  • Coordinate care with the multidisciplinary team, including metabolic specialists, dietitians, and social services.

Key Points

  • Education must be ongoing and adjusted as the child grows and nutritional needs change.
  • Nurses play a critical role in helping families integrate dietary management into normal life activities.

Important Clinical Alert

Artificial sweeteners containing aspartame (NutraSweet, Equal) are contraindicated in patients with PKU as aspartame is metabolized to phenylalanine. All food and medication labels should be checked for aspartame content.

Commonly Confused Points

Concept PKU Galactosemia Maple Syrup Urine Disease
Enzyme Deficiency Phenylalanine hydroxylase Galactose-1-phosphate uridyltransferase Branched-chain α-keto acid dehydrogenase
Dietary Restriction Phenylalanine (protein) Galactose and lactose Leucine, isoleucine, and valine
Characteristic Odor Musty/mousy None specific Maple syrup
Acute Complications Rarely acute Sepsis, liver failure Metabolic acidosis, coma
Long-term Effects Intellectual disability, seizures Cataracts, liver disease Intellectual disability, seizures

Study Tips

Memory Aid for PKU

P - Phenylalanine hydroxylase deficiency
K - Keep phenylalanine levels low with diet
U - Untreated leads to intellectual disability

Remember High-Phenylalanine Foods to Avoid

MEAT-PP
Meat and poultry
Eggs
Aspartame
Tofu and soy products
Peanuts and nuts
Products with high protein (cheese, milk)

Quick Check

What is the target phenylalanine level for children with PKU?

Answer: 2-6 mg/dL

Common Pitfalls

  • Confusing PKU with other metabolic disorders like galactosemia or maple syrup urine disease
  • Thinking treatment can be discontinued after childhood (it's lifelong)
  • Forgetting that maternal PKU can affect a fetus regardless of whether the fetus has PKU
  • Overlooking aspartame in medications and food products

Summary of Key Points

  • PKU is an autosomal recessive disorder caused by deficiency of phenylalanine hydroxylase, leading to elevated phenylalanine levels.
  • Newborn screening is essential for early detection before symptoms appear; treatment must begin within the first few weeks of life.
  • The primary treatment is a phenylalanine-restricted diet that must be maintained throughout life.
  • Untreated PKU results in progressive, irreversible neurological damage, including intellectual disability and seizures.
  • Women with PKU require strict metabolic control before and during pregnancy to prevent maternal PKU syndrome in the fetus.
  • Regular monitoring of blood phenylalanine levels guides dietary management.
  • Aspartame is contraindicated in patients with PKU as it is metabolized to phenylalanine.

Self-Assessment Checklist

I understand the pathophysiology of PKU
I can explain the importance of newborn screening for PKU
I know the dietary restrictions and management for PKU
I understand maternal PKU and its implications for pregnancy
I can identify key nursing interventions for patients with PKU
I recognize the importance of lifelong management for PKU

Remember, early detection and consistent management are the keys to successful outcomes in PKU. Your understanding of this condition can make a significant difference in a child's development and quality of life!

다음 이론을 계속 학습하려면 로그인하세요.

로그인하고 계속 학습
컨텐츠를 그만볼래?

필기노트, 하이라이터, 메모는 잘 쓰고 있어?

내보내줘
어떤 폴더에 저장할래?

컨텐츠 노트에는 총 0개의 폴더가 있어!

폴더 만들기
컨텐츠 만들기
만들기
신고했어요.

운영진이 검토할게요!

해당 유저를 차단했어요.

마이페이지에서 차단한 회원을 관리할 수 있어요.